The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Everolimus exposure and early metabolic response as predictors for treatment outcomes in breast cancer patients treated with everolimus and exemestane.
 
Annelieke Willemsen
Honoraria - Gilead Sciences
 
Lioe-Fee de Geus-Oei
Research Funding - GE Healthcare (Inst); Philips Healthcare (Inst); Siemens (Inst)
 
Maaike De Boer
Honoraria - AstraZeneca; Novartis
Consulting or Advisory Role - AstraZeneca; Novartis
Research Funding - Eisai; Novartis; Pfizer; Roche
 
Jolien Tol
No Relationships to Disclose
 
Yvonne Kamm
No Relationships to Disclose
 
Paul C. De Jong
Travel, Accommodations, Expenses - Roche
 
Allert Henrik Vos
Consulting or Advisory Role - SERVIER
Travel, Accommodations, Expenses - Roche
 
Jan Willem de Groot
Consulting or Advisory Role - Amgen; Bayer; Bristol-Myers Squibb; Celgene; Merck; MSD; Roche
 
Sasja F. Mulder
Travel, Accommodations, Expenses - Astellas Oncology
 
Erik H.J.G. Aarntzen
No Relationships to Disclose
 
Winald R. Gerritsen
Consulting or Advisory Role - Amgen; Astellas Pharma; Bayer; Bristol-Myers Squibb; CureVac; Janssen-Cilag; Merck Sharp & Dohme; Sanofi
Speakers' Bureau - Merck Sharp & Dohme
Research Funding - Astellas Pharma (Inst); Bayer (Inst); Janssen-Cilag (Inst)
Travel, Accommodations, Expenses - Amgen; Bayer; Merck Sharp & Dohme
 
Carla M.L.- Van Herpen
Consulting or Advisory Role - Bristol-Myers Squibb (Inst); Ipsen (Inst); Merck (Inst); MSD (Inst)
Research Funding - AstraZeneca (Inst); Merck (Inst); MSD (Inst); Novartis (Inst)
 
Nielka P. Van Erp
Speakers' Bureau - Sickmann Congress Organization
Research Funding - Astellas Oncology (Inst); AstraZeneca (Inst); Boehringer Ingelheim (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); Janssen-Cilag (Inst); Novartis (Inst); Pfizer (Inst); Roche (Inst); Sanofi (Inst)